DHR Health Institute for Research and Development Recognized as a “Top Performing Site” Once Again

Translate to Spanish or other 102 languages!

THREE-PEAT TEAM: The DHR Health Institute for Research and Development pictured here has been recognized as a “Top Performing Site” by SWOG (formerly the Southwest Oncology Group), one of the nation’s leading cancer clinical trials networks. This is the third consecutive time the Institute has received this prestigious recognition. Courtesy image
THREE-PEAT TEAM: The DHR Health Institute for Research and Development pictured here has been recognized as a “Top Performing Site” by SWOG (formerly the Southwest Oncology Group), one of the nation’s leading cancer clinical trials networks. This is the third consecutive time the Institute has received this prestigious recognition. Courtesy image
- Advertisement -

EDINBURG, Texas – The DHR Health Institute for Research and Development is delighted to announce that it has once again been recognized as a “Top Performing Site” by SWOG (formerly the Southwest Oncology Group), one of the nation’s leading cancer clinical trials networks. This marks the third consecutive time the Institute has received this prestigious distinction.

This recognition highlights the ongoing excellence and impact of the Research Institute as it continues to advance cancer research and improve patient outcomes.

“We are deeply honored and this recognition would not be possible without the assistance of the DHR Health Oncology Institute and the leadership of Dr. Jose Cruz,” said Dr. Scott Lillibridge, executive vice president for the DHR Health Institute for Research and Development.

- Advertisement -

SWOG is a global cancer research community supported by the National Cancer Institute (NCI), and recognition as a “Top Performing Site” signifies exceptional performance in clinical trial enrollment, data quality, and patient care standards.

The DHR Health Institute for Research and Development remains committed to innovation and delivering high-quality research opportunities to all residents of the Rio Grande Valley. They are located at 5323 S. McColl Road in Edinburg. For more information about clinical trials in the areas of liver, obesity, cancer, neurology, oncology and urology, call the Institute at (956) 362-2390.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

The Impact of Physical Activity on Parkinson’s Decline

For 68-year-old Robert Kennedy, a retired Florida Power and Light foreman, the secret to managing his Parkinson symptoms is movement.

FDA Approves First-of-Its-Kind Chronic Hepatitis B Treatment 

The U.S. Food and Drug Administration approved Hibsago (bepirovirsen) injection, in combination with existing antiviral therapy, to treat chronic hepatitis B virus (HBV) infection in certain adults without cirrhosis.

Social Security Administration Corrects Millions of Records in Major Database Cleanup

The Social Security Administration (SSA) announced on October 20, 2026, that it has corrected millions of Social Security number records in what the agency describes as its most comprehensive record-integrity initiative in 91 years.

FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women

The U.S. Food and Drug Administration approved the first generic of Climara Pro (estradiol and levonorgestrel transdermal system, 0.045 mg per day/0.015 mg), a transdermal hormone therapy patch for women with an intact uterus applied once a week. The approval aligns with FDA’s Public Health Pillar: Increasing Access to Affordable Medicines & Medical Products.
- Advertisement -